State Street Corp Cuts Position in MacroGenics, Inc. (MGNX)

State Street Corp lowered its position in MacroGenics, Inc. (NASDAQ:MGNX) by 3.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 969,221 shares of the biopharmaceutical company’s stock after selling 37,990 shares during the period. State Street Corp owned 2.63% of MacroGenics worth $16,974,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Cornerstone Capital Management Holdings LLC. raised its stake in shares of MacroGenics by 3.8% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,238 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 848 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of MacroGenics by 3.2% in the second quarter. Voya Investment Management LLC now owns 361,633 shares of the biopharmaceutical company’s stock valued at $6,332,000 after purchasing an additional 11,194 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of MacroGenics by 314.8% in the second quarter. Dimensional Fund Advisors LP now owns 180,739 shares of the biopharmaceutical company’s stock valued at $3,165,000 after purchasing an additional 137,167 shares in the last quarter. Hood River Capital Management LLC increased its holdings in shares of MacroGenics by 2.3% in the second quarter. Hood River Capital Management LLC now owns 576,193 shares of the biopharmaceutical company’s stock valued at $10,089,000 after purchasing an additional 13,050 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of MacroGenics in the second quarter valued at approximately $232,000. Institutional investors own 85.81% of the company’s stock.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the sale, the senior vice president now owns 35,000 shares of the company’s stock, valued at approximately $700,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.30% of the stock is currently owned by insiders.

A number of brokerages recently weighed in on MGNX. ValuEngine raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Citigroup raised their price target on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a report on Friday, November 10th. Cowen reissued a “buy” rating on shares of MacroGenics in a report on Wednesday, October 25th. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $34.00 price target on shares of MacroGenics in a report on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $30.10.

MacroGenics, Inc. (MGNX) traded down $0.52 on Wednesday, reaching $19.05. 248,332 shares of the company’s stock were exchanged, compared to its average volume of 262,117. MacroGenics, Inc. has a 12-month low of $14.36 and a 12-month high of $28.48.

MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $5.50 million. During the same period in the prior year, the firm posted ($0.97) EPS. MacroGenics’s revenue was down 48.5% on a year-over-year basis. equities analysts forecast that MacroGenics, Inc. will post -0.7 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/12/06/state-street-corp-has-16-97-million-holdings-in-macrogenics-inc-mgnx.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply